Isis Aims High With Lead Diabetes Drug, Still Saddled With Liver Effects
Executive Summary
In Phase II data presented at ADA, glucagon receptor antagonist ISIS-GCGR-Rx works well, but increase in liver enzymes persists as warning sign for the class. Nevertheless, Isis thinks the drug will one day step in when oral drugs start to falter – ahead of injectable GLP-1 agonists.